Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17459898 | 0.84 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL3058558 | 0.83 | CA12 (0.32) | — | |
| SCHEMBL28774141 | 0.82 | — | — | |
| SCHEMBL2897410 | 0.82 | — | — | |
| SCHEMBL28628369 | 0.80 | — | — | |
| SCHEMBL17336993 | 0.80 | CRBN (0.40) | — | |
| Hydrochloric Acid SCHEMBL6264288 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL6266097 | 0.78 | — | — | |
| SCHEMBL1708937 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL11804483 | 0.77 | CA12 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10369121-B2 | Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2019-08-06 | — | — | US | claimed |
| US-20170333370-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASES OR INFLAMMATORY DISEASES, CONTAINING BIGUANIDE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2017-11-23 | — | — | US | claimed |
| US-20090194124-A1 | Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine | MALLE GERARD | 2009-08-06 | — | — | US | claimed |
| US-20090139537-A1 | HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE | L'OREAL S.A. | 2009-06-04 | — | — | US | claimed |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | L'OREAL S.A. (FR) | 2005-06-23 | — | — | US | claimed |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | L'OREAL | 2005-06-16 | — | — | US | claimed |
| EP-0625967-A1 | N,N'-SUBSTITUTED IMIDOCARBONIMIDIC DIAMIDES DERIVED FROM HYDROXYLAMINES. | JACOBUS PHARMA CO INC (US) | 1994-11-30 | — | — | EP | claimed |
| CN-117062940-A | Composition and method for treating substrate | 富士胶片株式会社 | 2023-11-14 | — | — | CN | disclosed |
| CN-115746855-A | Treatment liquid | 富士胶片株式会社 | 2023-03-07 | — | — | CN | disclosed |
| WO-2022256419-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-08 | — | — | WO | disclosed |
| CN-114364780-A | Treatment liquid, kit, method for producing treatment liquid, method for cleaning substrate, and method for treating substrate | 富士胶片株式会社 | 2022-04-15 | — | — | CN | disclosed |
| WO-2021049208-A1 | TREATMENT LIQUID, KIT, TREATMENT LIQUID PRODUCTION METHOD, SUBSTRATE CLEANING METHOD, AND SUBSTRATE TREATMENT METHOD | 富士フイルム株式会社 | 2021-03-18 | — | — | WO | disclosed |
| CN-108485840-B | Cleaning formulation for removing residues on surfaces | 富士胶片电子材料美国有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-20030234063-A1 | Non-toxic corrosion-protection conversion coats based on cobalt | DAYTON, UNIVERSITY OF | 2003-12-25 | — | — | US | disclosed |
| US-20030230363-A1 | Non-toxic corrosion-protection rinses and seals based on cobalt | UNIVERSITY OF DAYTON | 2003-12-18 | — | — | US | disclosed |
| CN-1457773-A | Biguanide vanadium complex granular powder and/or capsule for curing diabetes and its use | YUE YI (CN) | 2003-11-26 | — | — | CN | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060191-A2 | NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060019-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| CN-1285866-A | Disinfecting contact lenses with bis (biguanides) and polymeric biguanides | BAUSCH & LOMB (US) | 2001-02-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10369121-B2 | Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient | IL17A, TNF, IL2 | NOS3 233/4885NOS1 327/4885NOS2 212/4885 |
| US-20090139537-A1 | HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE | KRT18, INMT, INHA | NOS3 323/4885NOS1 166/4885NOS2 147/4885 |
| US-20090194124-A1 | Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine | KRT18, KIT, PRDM7 | NOS3 1293/4885NOS1 591/4885NOS2 621/4885 |
| US-20170333370-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASES OR INFLAMMATORY DISEASES, CONTAINING BIGUANIDE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | IL17A, TNF, IL2 | NOS3 233/4885NOS1 327/4885NOS2 212/4885 |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | KRT18, INHA, H1-5 | NOS3 1322/4885NOS1 681/4885NOS2 767/4885 |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | BHMT, KRT18, INMT | NOS3 634/4885NOS1 200/4885NOS2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.